Profitability Metrics

Gross Margin
31.07%
Operating Margin
15.86%
Net Margin
11.84%

Efficiency Metrics

Revenue per Expense Ratio
1.20
R&D as % of Revenue
1.89%

Earnings Quality

EBITDA Margin
17.65%
Income Tax Rate
19.99%
EPS
16.6200000000

Balance Sheet Analysis

Current Ratio
1.41
Cash Ratio
0.07
Working Capital
$418.90M
Debt to Equity
5.35
Debt to Assets
54.58%
Equity Ratio
10.20%

Cash Flow Analysis

Operating Cash Flow Ratio
14.72%
Free Cash Flow Ratio
9.69%
CapEx to Revenue
5.02%
Dividends Paid
$153.40M
Stock Buybacks
$14.90M
Total Shareholder Returns
$168.30M
Cash Position Change
15.40%

Key Takeaways (2023 FY)

  • Maintained positive net income growth despite revenue changes
  • Increased dividend payments by 8.64%
  • Increased R&D investment by 17.06%

Detailed Growth Metrics

Core Performance

Revenue
5.58%
Net Income
18.71%
EPS
19.40%
Operating Income
20.41%

Operational Efficiency

R&D Expenses
17.06%
SG&A Expenses
12.48%
Operating Cash Flow
143.53%
Free Cash Flow
141.55%

Balance Sheet Health

Assets
8.99%
Debt
-12.72%
Book Value per Share
241.26%
Inventory
-7.16%

Shareholder Returns

Dividends per Share
8.64%
Shares Outstanding
-0.56%

Long Term Trends

3Y Revenue/Share
47.90%
5Y Revenue/Share
46.70%
3Y Dividend/Share
40.13%
5Y Dividend/Share
86.83%